526
Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.
 2 patients: Subject; 2: Subject.Population; CD8+ cutaneous lymphoproliferative: Effect; efalizumab and infliximab: Treatment; efalizumab: Treatment.Drug; infliximab: Treatment.Drug; efalizumab: Combination.Drug; infliximab: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 2 patients: Subject; 2: Subject.Population; CD8+ cutaneous lymphoproliferative: Effect; efalizumab and infliximab: Treatment; efalizumab: Treatment.Drug; infliximab: Treatment.Drug; efalizumab: Combination.Drug; infliximab: Combination.Drug